CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 960,731 shares, a decline of 41.8% from the June 30th total of 1,651,945 shares. Based on an average daily volume of 406,881 shares, the days-to-cover ratio is presently 2.4 days. Currently, 10.4% of the company’s stock are sold short.

Insider Activity

In other CalciMedica news, Director Fred A. Middleton bought 248,972 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the transaction, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. This trade represents a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 28.25% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers increased its holdings in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the last quarter. 180 Wealth Advisors LLC raised its position in shares of CalciMedica by 297.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after acquiring an additional 94,650 shares in the last quarter. Renaissance Technologies LLC lifted its stake in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares during the last quarter. Jane Street Group LLC bought a new position in CalciMedica during the fourth quarter worth $127,000. Finally, Envestnet Asset Management Inc. boosted its holdings in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the period.

CalciMedica Stock Performance

Shares of CALC stock opened at $1.00 on Friday. The stock has a market capitalization of $15.80 million, a price-to-earnings ratio of -0.76 and a beta of 0.89. CalciMedica has a one year low of $0.46 and a one year high of $7.20. The company’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.10.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CALC shares. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CalciMedica has a consensus rating of “Hold” and a consensus price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.